Ball Robert Joseph sold $188K of SI

Ball Robert Joseph (CEO & Executive Chairman) sold 10,175 shares of SHOULDER INNOVATIONS, INC. (SI) at $18.45 ($0.19M total) on 2026-09-14.

Original reporting
SEC EDGAR · Ball Robert Joseph
Published Sep 15, 2026, 12:23 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 12:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SI
Neutral
medium confidence
Mentioned
$SI
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SINeutralLow
01

Why it matters

The sale is modest and unlikely to move the stock significantly, but may be noted by short-term traders.

02

Market read

Small insider sale with limited market impact.

03

What to watch

No change in company fundamentals; sale may be unrelated to performance.

Relevance 4/10Novelty 4/10Timing: post-market 2026-09-14 filing

Background

Form 4 filing provides the first public disclosure of the insider transaction.

Company-level read

Ticker impact

$SINeutralMedium confidence
Context

CEO Robert Ball sold 10,175 shares of Shoulder Innovations for $187,706, reducing his stake to 380,824 shares.

Expected impact

Potential slight downward pressure on SI price.

Evidence & confidence

Sale amount is under $200K and represents a small percentage of total holdings; market reaction likely limited.

Market effects

Minor signal for biotech sector insider activity.

U.S. market only.

Low

Counterpoint

Insider sale could be routine liquidity need, not a negative signal.

Key entities

  • Shoulder Innovations, Inc.

    Biotech firm listed on NASDAQ under ticker SI.

  • Robert Ball

    CEO and Executive Chairman of Shoulder Innovations.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SIMedAI 8/10

Shoulder Innovations (SI) Q3 2026 Earnings Call Transcript

Shoulder Innovations reported Q3 2026 net revenue of $16.2M, up 38% YoY, with gross margin at 78.5%. The company raised full-year revenue guidance to $68M-$70M, up 44%-48% YoY. They launched new products, including the InSet Go glenoid implant, and saw strong surgeon adoption and procedural growth. The company expects continued momentum and plans to expand its commercial team.

$SIHigh

Shoulder Innovations Reports Third Quarter 2026 Financial Results and Raises Full Year Outlook

SHOULDER INNOVATIONS, INC. (SI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Shoulder Innovations Reports Third Quarter 2026 Financial Results and Raises Full Year Outlook 52% Year-to-Date 2026 Revenue Growth Grand Rapids, MI – November 5, 2026 – Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage

$SIMed

22 Humeral Head and Initiates Full Commercial Launch – Ortho Spine News

Shoulder Innovations (NYSE: SI) received FDA 510(k) clearance for its N-22 Humeral Head, a titanium implant for metal-sensitive patients. The company also launched the product commercially. The N-22 Humeral Head complements the N-22 Glenosphere, cleared earlier this year, for use in shoulder arthroplasty procedures. According to the company, this expansion may enhance surgeon relationships and operational centers. Shoulder Innovations focuses on shoulder surgical care, offering advanced implant

$SIMed

Shoulder Innovations Q2 Earnings Call Highlights

Shoulder Innovations (NYSE:SI) reported Q2 gross margin of 78.3% versus 76.2% a year earlier, with SG&A rising to $20.1M and R&D to $3.4M. Net loss narrowed to $10.2M. Cash totaled $99M at June 30. The company expects similar gross margins in 2H 2026 and plans FDA submissions for its robotic platform in 2027.